Trastuzumab pamirtecan
Antibody–drug conjugate
Also known as DB-1303
Evidence outlook · regulatory review
HER2-Positive Breast Cancer: application under NMPA review
NMPA accepts BLA for trastuzumab pamirtecan (DB-1303) (2026-04-09). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.
NCT06265428: Patients were randomly assigned to DB-1303/BNT323 or the active comparator T-DM1 in a Phase 3 trial of about 228 patients, with disease progression (PFS) as the primary measure -- a hard clinical endpoint. However, the study is open-label with no blinding of patients or investigators, and while outside reporting indicates the drug beat T-DM1 on PFS at an interim look, no specific numbers (hazard ratio, medians, or p-value) are available to verify the strength of that result, so this is graded as solid but not top-tier evidence.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Also in development:HR+/HER2- Metastatic Breast Cancer · Phase 3Endometrial Cancer · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06265428 NCT06265428 · HER2-positive Breast Cancer Patients were randomly assigned to DB-1303/BNT323 or the active comparator T-DM1 in a Phase 3 trial of about 228 patients, with disease progression (PFS) as the primary measure -- a hard clinical endpoint. However, the study is open-label with no blinding of patients or investigators, and while outside reporting indicates the drug beat T-DM1 on PFS at an interim look, no specific numbers (hazard ratio, medians, or p-value) are available to verify the strength of that result, so this is graded as solid but not top-tier evidence. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. Registry: NCT06265428 | 3 | Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) assessment per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (Up to approximately 24 months.) 2027-12 | NCT06265428, primary endpoint progression-free survival: BNT323/DB-1303 (trastuzumab pamirtecan) vs T-DM1 met the primary PFS endpoint at a pre-specified interim analysis. | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 1/2 (2)
What this study did
What this study did
Competitive landscape
Other HER2 drugs
margetuximab, Trastuzumab Deruxtecan, Tucatinib, Zanidatamab, Disitamab Vedotin and 11 more. Compare all 17 HER2 drugs
This mechanism is crowded: 16 other tracked programmes target it, 4 of them ahead of this one.
This drug's own stage for HER2-Positive Breast Cancer: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Trastuzumab Pamirtecan: this drug | Phase 3 | Antibody–drug conjugate | HER2 | Partial signal | NCT06265428: NCT06265428, primary endpoint progression-free survival: BNT323/DB-1303 (trastuzumab pamirtecan) vs T-DM1 met the primary PFS endpoint at a pre-specified interim analysis. | |
| Margetuximab (Margenza) | Approved | Monoclonal antibody | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Neratinib | Approved | Small molecule | EGFR/HER2 | Reliable signal | NCT00878709: Invasive Disease-free Survival (iDFS) in Neratinib Arm Compared to Placebo Arm at Year 2 (From randomization until time of event up to 2 years): Neratinib 4.7 percentage of participants with events vs Placebo 7.5 percentage of participants with events | |
| Palbociclib (Ibrance) | Approved | Small molecule | CDK4 and CDK6 | not yet graded | No reviewed efficacy summary in this indication | |
| Pertuzumab | Approved | Monoclonal antibody | HER2/neu Receptor Antagonist | Reliable signal | NCT01358877: IDFS events, pertuzumab + trastuzumab + chemotherapy vs placebo + trastuzumab + chemotherapy: 7.1% vs 8.7%, hazard ratio 0.81 (95% CI 0.66 to 1.00), p=0.0446 (log-rank); 3-year IDFS event-free rate 94.06% vs 93.24% (CT.gov posted results, data cut-off 19 December 2016). NCT00567190: IRF-assessed progression-free survival, pertuzumab + trastuzumab + docetaxel vs placebo + trastuzumab + docetaxel: median 18.5 vs 12.4 months, hazard ratio 0.62 (95% CI 0.51 to 0.75), p<0.0001 (stratified log-rank; CT.gov posted results). | |
| Trastuzumab Deruxtecan | Approved | Antibody–drug conjugate | HER2 | Partial signal | NCT03523585: Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine (Baseline up to 46 months postdose): Trastuzumab Deruxtecan (T-DXd) 17.8 months (95% CI 14.3 to 20.8) | |
| Trastuzumab Emtansine | Approved | Antibody–drug conjugate | HER2 (ERBB2) | Partial signal | Featured results are non-efficacy only in this race | |
| Tucatinib | Approved | Small molecule | HER2 | Reliable signal | NCT05132582: HER2CLIMB-05 (NCT05132582), primary endpoint PFS: median 24.9 months with tucatinib vs 16.3 months with placebo; HR 0.641 (95% CI 0.514-0.799); P<.0001. NCT03975647: Progression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 Based on Investigator Assessment (From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 43 months)): Tucatinib+ Ado-trastuzumab Emtansine 9.5 Months (95% CI 7.4 to 10.9) vs Placebo+ Ado-trastuzumab Emtansine 7.4 Months (95% CI 5.6 to 8.1) | |
| Anbenitamab Repodatecan | Phase 3 | Antibody–drug conjugate | HER2 (biparatopic — extracellular domains II and IV) | not yet graded | No reviewed efficacy summary in this indication | |
| Docetaxel (HB1801) | Phase 3 | Small molecule | Microtubules (tubulin) | not yet graded | No reviewed efficacy summary in this indication | |
| Pyrotinib | Phase 3 | Small molecule | EGFR/HER1, HER2, HER4 | not yet graded | No reviewed efficacy summary in this indication | |
| Trastuzumab Brengitecan | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Trastuzumab Rezetecan | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Zanidatamab | Phase 3 | Multispecific antibody | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Bizrolertinib | Phase 2/3 | Small molecule | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Disitamab Vedotin | Phase 2/3 | Antibody–drug conjugate | HER2 | Partial signal | NCT03500380: Median progression-free survival assessed by blinded independent review committee (phase 3 stage, 104 patients randomized): 9.9 months with disitamab vedotin versus 4.9 months with lapatinib plus capecitabine; stratified hazard ratio 0.56 (95.48% CI: 0.35-0.91). | |
| Evorpacept | Phase 2 | Protein / enzyme therapeutic | CD47 | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-4508 | Phase 2(overall) | Small molecule | HER2 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| 177Lu-DWJ155 | Phase 1(overall) | Radiopharmaceutical | HER2 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| BBO-10203 | Phase 1(overall) | Small molecule | RAS:PI3Kα protein-protein interaction | not yet graded | No reviewed efficacy summary in this indication | |
| BL-M17D1 | Phase 1(overall) | Antibody–drug conjugate | HER2 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| KJ015 | Phase 1(overall) | Multispecific antibody | HER2 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| MT-304 | Phase 1(overall) | RNA / oligonucleotide | HER2 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| NVL-330 | Phase 1(overall) | Small molecule | HER2 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| RAD202 | Phase 1(overall) | Radiopharmaceutical | HER2 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| GSK6855547 | —(overall) | Small molecule | HER2 | not yet graded(overall) | No reviewed efficacy summary in this indication |
Compare side by side
2 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Trastuzumab pamirtecan to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent